GSK enters agreement to acquire Aiolos Bio
Issued: London, UK
For media and investors only
Download
(PDF, 235.3KB)
Acquisition expands GSK’s respiratory pipeline adding AIO-001, a phase II-ready, long-acting antibody targeting the clinically validated TSLP pathway
AIO-001 could redefine...
Zur Pressemeldung auf www.gsk.com